Collegium: Use Pain Cash Flow to Back an ADHD Re-rating — Buy for a 50% Upside

Hook & thesis

Collegium (COLL) is no longer just a pain-management royalty-style story — it is a cash-generative platform funding an explicit push into ADHD. The company closed the AZSTARYS acquisition for approximately $650 million on 05/12/2026, raised 2026 guidance to $865-$895 million in total product revenues and $475-$500 million in adjusted EBITDA, and still sits on free cash flow of $329,826,000. Those numbers matter: at a market cap near $1.15 billion and an enterprise value of $1.682 billion, the stock is trading at a low single-digit EV/EBITDA multiple versus its newly guided, higher-margin profit profile.

My trade idea: buy COLL at or under the current price to play a re-rating driven by AZSTARYS integration, continued Jornay PM momentum, and evidence-driven marketing (including high-profile awareness campaigns). If management executes, the market should assign a higher multiple to the combined ADHD franchise. Given the company's extraordinary free cash flow conversion and attractive valuation, I see a clear asymmetric upside — target $50 — with a defined stop at $30 to respect the firm's exposure to commercialization execution and regulatory/market risks.

What Collegium does and why it matters

Collegium is a specialty biopharmaceutical company focused on central nervous system and pain medicines with formulation and delivery innovation. Its marketed portfolio includes Xtampza ER, Nucynta ER/IR, Belbuca, Symproic and ADHD products including Jornay PM. The strategic move in 2026 was the acquisition of AZSTARYS, an ADHD medication purchased from Corium Therapeutics for roughly $650 million on 05/12/2026, with patent protection through 2037. Management says the deal is immediately accretive and expects annual synergies in excess of $50 million.

The market should care because Collegium is converting legacy pain cash flows into growth capital for ADHD — a category with higher commercial runway and less regulatory stigma than pure opioid products. Jornay PM already demonstrated fast growth (reported +48% in its first full year in one filing) and recent Q1 2026 net revenues of $193.5 million were up 9% year-over-year, with Jornay PM revenues up 36% year-over-year. The AZSTARYS asset helps diversify the revenue base and accelerates share gains in a high-value specialty community.

Hard numbers that back the thesis

Those figures are eyeball-grabbing. Trailing free cash flow of roughly $330 million against a market cap just north of $1.14 billion implies a FCF yield in the high twenties. Even ignoring one-time integration items, the company's 2026 adjusted EBITDA guidance midpoint of $487.5 million implies an EV/adj-EBITDA of roughly 3.45x (EV $1.682 billion / $487.5 million midpoint). That is compelling for a company that expects to grow its ADHD footprint and to extract >$50 million in synergies from AZSTARYS.

Valuation framing

Collegium currently trades at single-digit EV/EBITDA and mid-teens P/E using trailing metrics, while near-term guidance implies an even lower multiple. Put another way: the market is valuing the combined business conservatively despite strong cash generation and a newly accretive acquisition. There are reasons for a discount — legacy exposure to opioid labeling and the complexity of integrating a branded ADHD product — but on core numbers alone the stock looks inexpensive relative to the earnings and cash generation guidance management provided for 2026.

Without peer multiples in the payload, judging absolute cheapness is necessarily qualitative. Still, a sub-4x EV/EBITDA and sub-4x price-to-free-cash-flow multiple for a profitable specialty pharma with durable patents (AZSTARYS through 2037) and growth on the ADHD side is unusual. If the market re-assesses risk and gives the combined ADHD franchise a more typical growth-pharma multiple, a move toward $50 is plausible.

Catalysts to make this trade work

• AZSTARYS integration and synergies realization - management expects >$50 million in annual synergies; early signs of cost or commercial synergies would catalyze re-rating.
• Continued Jornay PM momentum and scaling - Jornay PM grew strongly (reported +36% or +48% in filings), and higher adoption supports the thesis that ADHD can replace declining pain volumes over time.
• High-visibility awareness campaigns and partnerships - the Paris Hilton "Embrace Your Sparkle" campaign (03/03/2026) raises ADHD awareness and can accelerate diagnosis-and-treatment funnels.
• Investor events and data flow - management's participation in the Jefferies Global Healthcare Conference (06/03/2026) and upcoming RWD/poster data at PainConnect and nurse practitioner conferences provide incremental visibility.
• Guidance consistency - the raised 2026 revenue and adjusted EBITDA guidance ($865-$895M revenue; $475-$500M adj EBITDA) leaves room for positive surprises if demand proves stickier than expected.

Trade plan

Action: Buy COLL at or below $35.40 (current price). Entry price: $35.40. Target: $50.00. Stop loss: $30.00.

Horizon: Long term (180 trading days). Expect the re-rating to unfold over multiple quarters as AZSTARYS is integrated, synergies are realized and ADHD prescriptions scale. The 180 trading day horizon gives the market time to digest quarterly cadence, commercial read-throughs, and early integration metrics.

Shorter holds: if you prefer a shorter look, treat this as a mid term (45 trading days) swing around major catalysts (conference commentary or an integration update). For short-term traders (10 trading days), keep position size small: volatility around integration headlines and short interest that has occasionally produced heavy short days can create choppy price action.

Position sizing and risk management

• Risk level: medium. The balance sheet and FCF reduce solvency risk, but commercial execution and perception shifts in opioid-related product lines create headline risk.
• Use a stop at $30.00 to limit downside — this preserves capital below recent technical support and keeps the trade manageable if market sentiment turns on commercialization worries.
• Consider trimming into strength near $45 and adding again on pullbacks if fundamentals remain supportive.

Risks and counterarguments

Counterargument: The market is discounting Collegium for good reasons — legacy pain-market exposure, reputational/regulatory overhang, and the risk that AZSTARYS doesn't scale as hoped. If ADHD uptake disappoints or if patient-level persistence and payer coverage fall short, the supposed re-rating could evaporate quickly.

• Commercial execution risk: AZSTARYS is a newly acquired product and integration execution (salesforce alignment, payer contracting, promotion) is not guaranteed. Missed synergies or slower sales growth would undermine valuation.
• Payer & reimbursement risk: ADHD treatments face payer scrutiny; formulary placement and step therapy dynamics could blunt uptake or increase discounting.
• Regulatory & reputational risk: Collegium's legacy opioid/pain portfolio attracts extra scrutiny; any adverse headlines or regulatory actions could pressure valuation and distract management.
• Market multiple compression: Even with strong results, the broader healthcare sector or small-cap biotech space could re-rate lower, limiting upside irrespective of company-specific progress.
• Short-squeeze/choppy technicals: Elevated short interest and episodic heavy short volume days can create unpredictable price swings that hurt momentum-based entries.

What would change my mind

I will re-evaluate the bullish stance if any of the following occur: (a) management misses its 2026 revenue or adjusted EBITDA guidance materially, (b) AZSTARYS materially underperforms initial commercial expectations or synergies fall short by a large margin, (c) new negative regulatory developments materially change prescribing behavior for ADHD or pain products, or (d) free cash flow conversion deteriorates meaningfully. Conversely, if the company beats guidance, shows early synergy capture and delivers accelerating ADHD revenue growth, I would increase the target and reduce the stop.

Conclusion

Collegium offers an actionable asymmetric trade: buy at or below $35.40 with a $50 objective over ~180 trading days and a $30 stop. The thesis rests on strong cash generation, an accretive AZSTARYS purchase, clear guidance and multiple visible catalysts. The primary risks are commercial execution, payer dynamics and headline/regulatory noise — manageable if position sizing and stops are respected. For investors who want a defined-risk way to play ADHD exposure funded by stable pain cash flows, COLL looks like a high-conviction tactical position.